Founded in Wakefield, United States, Galenea is dedicated to developing therapeutics for central nervous system diseases. The company's core mission is to address the unmet medical needs in neurological and psychiatric disorders through innovative drug development. Galenea focuses on creating effective treatments that improve the quality of life for patients suffering from conditions such as schizophrenia, depression, and Alzheimer's disease.
Galenea has attracted notable investors and collaborators in the biotech and pharmaceutical industries. The company has achieved significant milestones in preclinical and clinical trials, demonstrating the potential of its therapeutic candidates. Through its pioneering research and development efforts, Galenea aims to make a substantial impact on the treatment landscape for central nervous system diseases, offering hope to millions of patients worldwide.